This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers
Gavi launches new learning initiative to address the final barriers to immunisation equity

- **Reaching the millions of “zero-dose” children** who have yet to receive a single vaccine represents one of the final – and most complex – barriers to overcome in the push for global immunisation equity
- **Gavi will fund and coordinate the Zero-Dose Learning Hub (ZDLH), a network of global and national organisations focused on collecting and sharing high-quality data, evidence and learning – and helping transform these into effective action, particularly in lower-income countries**
- **JSI Research and Training Institute, Inc. (JSI) will lead the global hub with support from the Indian Institute of Health Management Research (IIHMR) and The Geneva Learning Foundation (TGLF)**

Geneva, 13 April 2023 – Gavi, the Vaccine Alliance (Gavi) has launched the Zero-Dose Learning Hub (ZDLH), a new mechanism to improve how data and evidence are leveraged to successfully identify and reach the millions of children who have not yet received a single routine vaccine shot – “zero-dose” children – and the missed communities in which they live.

The goal of the ZDLH collaboration is to supplement existing and ongoing monitoring efforts by building deeper understanding and sharing learning on the complex array of factors that impact efforts to reach zero-dose children, particularly in lower-income Gavi implementing countries.

Funded and coordinated by Gavi, ZDLH is composed of Country Learning Hubs in Bangladesh, Mali, Nigeria and Uganda, as well as a global hub led by JSI Research and Training Institute, Inc. (JSI), with support from the Indian Institute of Health Management Research (IIHMR) and The Geneva Learning Foundation (TGLF). The global hub will provide technical and operational support to countries; and disseminate learning across immunisation stakeholders at the community, national, regional and global levels.

“Zero-dose children face significant and complex systemic barriers that impact their ability to access basic services, including immunisation,” said Thabani Maphosa, Managing Director of Country Programmes Delivery at Gavi. “Since the inception of our Alliance, Gavi has taken a data-driven approach to address immunisation challenges. This new investment will help inform and improve immunisation programmes to reach the most vulnerable children in urban slums, rural and hard-to-reach areas, and fragile and conflict settings – using tailored approaches and addressing gender-related barriers. Today’s new partnership is another important step in our mission to ensure no child misses out on life-saving vaccines, no matter where they live.”

... The number of zero-dose children in Gavi implementing countries reduced by 14% from 2015 to 2019. However, this number increased during the pandemic; and in 2021, there were 12.5 million zero-dose children in the 57 lower-income countries supported by Gavi.

As a result, during the 2021–2025 strategic period, Gavi and Alliance partners are focused on reaching zero-dose children and missed communities, aiming to leverage the power of innovation and new
partnerships to reduce the number of zero-dose children in Gavi-eligible countries by 25% by 2025.

Today’s ZLDH launch represents the latest initiative in this effort, alongside Gavi’s Zero-Dose Immunization Programme (ZIP), an innovative initiative that is providing two consortia of partners with up to US$ 100 million to identify and reach zero-dose children living in displaced communities and fragile and conflict settings...

The four Country Learning Hubs – in Bangladesh, Mali, Nigeria and Uganda – will be led by a variety of organisations with specific in-country knowledge:
- Bangladesh – International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) with Jhpiego and RedOrange Media and Communications;
- Mali – GanashAID with Center for Vaccine Development-Mali (CDV-Mali);
- Nigeria – African Field Epidemiology Network (AFENET) with Africa Health Budget Network (AHBN);
- Uganda – Infectious Diseases Research Collaboration (IDRC) and its consortium partners, consisting of PATH and Makerere University School of Public Health.

::::::
::::::

A brief overview of the Preparedness and Resilience for Emerging Threats initiative (PRET)
14 April 2023  WHO Departmental news
To better prepare for the next pandemic, or even better, to prevent it, WHO is launching an initiative to help countries ensure they have the systems and capacities in place to speed up every aspect of their management of emerging threats, from response and recovery.

The Preparedness and Resilience for Emerging Threats initiative, or PRET for short, is launching first with a focus on respiratory pathogens. On 24-26 April, WHO will host a global meeting on PRET to usher in the new era of pandemic preparedness and initial focus on respiratory pathogen pandemic preparedness. Expected outputs from the meeting include a global Call to Action and a global roadmap for implementation.

PRET focuses on improving pandemic preparedness for groups of pathogens based on their mode of transmission. It recognizes that there are three tiers of systems and capacities relevant for pandemic preparedness: those that are cross-cutting for all or multi-hazards, those that are relevant for groups of pathogens (respiratory, arboviruses etc.), and those that are specific to a pathogen. The aim is to strengthen existing systems and capacities, and to fill gaps. This approach avoids siloes, promotes coherence and efficiency, and helps streamline actions at the time of a pandemic.

With the ever-present risk of an influenza or other respiratory pathogen pandemic, PRET’s first module looks at pandemic preparedness for respiratory pathogens. PRET will develop more modules for other pathogen groups as we move forward. Each module is intended to be a living document so that new learnings and innovations are incorporated over time...

...PRET focuses on strengthening and sustaining preparedness systems and health system resilience; monitoring of capacity building efforts; and promoting a whole-of-government and whole-of-society approach for pandemic planning. As PRET modules are designed to be living documents, they will...
adapt to the direction set by Member States through the Pandemic Accord. See the figure outlining PRET’s fit within the broader context...

Getting access to novel COVID-19 treatments: Launch of Member States briefing on how to navigate interfaces between public health and intellectual property

Media Release
Geneva, 11 April 2023 – The World Health Organization and Unitaid, with the support of Medicines Law & Policy, have today published a briefing document to support country access to affordable COVID-19 treatments.

This briefing document is a factual explanation of some of the legal instruments that WHO Member States can use to promote public health and access to COVID-19 therapeutics in the framework of their multilateral trade obligations and rights, and according to their national legislation and level of development. It is intended to support countries dealing with challenges at the intersection of public health and intellectual property, to increase access to novel COVID-19 therapeutics and to facilitate alternative and more affordable sourcing of such treatments, where possible.

Member States should use all tools available to them and this briefing documents clearly spells out what those are including voluntary licenses to overcome intellectual property barriers. Countries that are not covered by voluntary licenses are encouraged to use to the full flexibilities under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement) and the Doha Declaration on the TRIPS Agreement and Public Health.

WHO Assistant Director-General, Prof. Hanan Balkhy said, “I urge Member States to implement all the available tools they have to make local production possible and to improve access. This includes licenses for access, the use of TRIPS flexibilities and the implementation of the WTO TRIPS decision. WHO will continue providing technical assistance on how to make use of these instruments.”

Dr Philippe Duneton, Executive Director of Unitaid added “It is crucial to prioritize the availability and accessibility of essential health technologies worldwide. By harnessing all tools at our disposal, we can increase access to essential health products and, ultimately, save more lives. At Unitaid, we remain committed to working with our partners to explore all solutions that will enable us to overcome the challenges posed by the pandemic and build a more resilient health system for the future.”

Improving access to novel COVID-19 treatments: A briefing to Member States on how to navigate interfaces between public health and intellectual property

2023 :: 40 pages

Member States briefing prepared by Unitaid (Anne-Isabelle Cameron, Karin Timmermans, Carmen Pérez Casas) and WHO (Erika Dueñas Loayza) with the support of Medicines Law & Policy (Kaitlin Mara, Ellen ’t Hoen, Pascale Boulet).
In 2022, Unitaid, as co-lead of the ACT-A Therapeutics pillar, convened focused discussions with relevant experts and pillar members, including the World Health Organization (WHO), on the interface between access to COVID-19 therapeutics and intellectual property. An outcome of this meeting was a request for Unitaid and WHO to co-publish a briefing document for countries on pathways for countries to access more affordable therapeutic options.

This briefing document is a factual explanation of some of the legal instruments that Member States are allowed to use to promote public health and access to key therapeutics, in the framework of their
multilateral trade obligations and rights and according to their national legislations and level of development.

The document is in line with WHO's mandate, included in several WHA Resolutions like the Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (GSPA-PHI)(WHA 61.21 and further Resolutions and Decisions on the implementation of the Plan of Action) to provide technical assistance to Member States in the application and management of intellectual property to contribute to innovation and to promote public health.

---

**PHEIC**

**Coronavirus [COVID-19] - WHO**

Public Health Emergency of International Concern (PHEIC)


**Weekly Epidemiological and Operational updates**

Last update: 29 March 2023

- **Confirmed cases**: 762 791 152
- **Confirmed deaths**: 6 897 025
- **Vaccine doses administered**: 13 337 964 733

**Weekly epidemiological update on COVID-19 - 13 April 2023**

**Overview**

Globally, 3 million new cases and over 23 000 deaths were reported in the last 28 days (13 March to 9 April 2023), a decrease of 28% and 30%, respectively, compared to the previous 28 days (13 February to 12 March 2023).

Contrary to the overall trend, important increases in reported cases and deaths were seen in the South-East Asia and Eastern Mediterranean regions and in several individual countries elsewhere. As of 9 April 2023, over 762 million confirmed cases and over 6.8 million deaths have been reported globally.

**Figure 1. COVID-19 cases reported by WHO Region, and global deaths by 28-day intervals, as of 9 April 2023**
**WHO policy brief: COVID-19 surveillance, 11 April 2023**

11 April 2023

**Overview**

**Key points**

- Countries are advised to maintain core SARS-CoV-2 surveillance activities to meet key strategic objectives. WHO continues to request that Member States continue reporting surveillance variables previously specified in guidance documents.

- Multiple approaches should be applied to surveillance, including describing infection in populations at highest risk of severe infection, characterizing new variants and investigating post-COVID condition.

- Although national testing strategies are adjusting to a decline in the impact of COVID-19, SARS-CoV-2 testing should continue but be used strategically, while being integrated into longer-term respiratory pathogen surveillance.

- While reporting requirements will change as the pandemic progresses, WHO has urged Member States to provide more reporting on hospitalizations, ICU and mortality and relies on these data, rather than on case-based reporting, to measure burden and impact.

- It is crucial to strengthen genomic surveillance for SARS-CoV-2 and other pathogens with epidemic and pandemic potential. Testing and reporting strategies should be linked to genomic surveillance and phenotypic assessment.

- Strengthening COVID-19 systems leads the way to enhanced pandemic preparedness for respiratory pathogens. Countries are urged to maintain operational readiness for surges of COVID-19 and other emerging and re-emerging pathogens.

- WHO encourages its Member States to improve data linkage, share data and experiences and explore more innovative and collaborative ways of working to detect outbreaks early and fully understand risks and vulnerabilities.

---

**COVID-19 Data Explorer: Global Humanitarian Operations**

**COVID-19 Vaccine Roll-out**

**Apr 03, 2023** | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | DATA

Global COVID-19 Figures: 126M total confirmed cases; 2.3M total confirmed deaths

Global vaccines administered: 13.4B

Number of Countries: 28

COVAX Allocations Round 4-9 (Number of Doses): 170M

COVAX Delivered (Number of Doses): 390M

Other Delivered (Number of Doses): 430M

Total Delivered (Number of Doses): 830M

Total Administered (Number of Doses): 610M

---
**Our World in Data**

**Coronavirus (COVID-19) Vaccinations**  [Accessed 15 Apr 2023]

:: 69.9% of the world population has received at least one dose of a COVID-19 vaccine.
:: 13.37 billion doses have been administered globally, and 257,651 are now administered each day.
:: 29.3% of people in low-income countries have received at least one dose.

---

**Global Dashboard on COVID-19 Vaccine Equity**

The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

**Dashboard on Vaccine Equity** [accessed 15 Apr 2023]: [https://data.undp.org/vaccine-equity/](https://data.undp.org/vaccine-equity/)

See also visualization on [Vaccine Access](https://data.undp.org/vaccine-access) and [Vaccine Affordability](https://data.undp.org/vaccine-affordability)
Global COVID-19 Access Tracker
https://www.covid19globaltracker.org/

High income countries: 3 in 4 people, or 72.8% have been vaccinated with at least one dose as of Apr 12, 2023.

Low income countries: 1 in 3 people, or 32.95% have been vaccinated with at least one dose as of Apr 12, 2023.

High income countries have to increase their health care spending by 0.8% on average to cover cost of vaccinating 70% of the population.

Low income countries have to increase their health care spending by 56.6% on average to cover cost of vaccinating 70% of the population.

The ACT-Accelerator Global COVID-19 Access Tracker (GCAT) is a dynamic tool to transparently track progress on access to COVID-19 vaccines, treatments, tests, and PPE.

- **Vaccination**: 1.93 Bn doses delivered by COVAX to date, 146 countries with vaccine doses through COVAX
- **Testing**: 176 Mn tests delivered via ACT-A to date, 184 countries with tests delivered via ACT-A
- **Therapeutics**: 313,558 therapeutics allocated to countries that are confirmed
- **Health Workers**: US$ 736 Mn Personal Protective Equipment (PPE) delivered via ACT-A to date

Updated on Mar 30, 2023  Methodology  Download the data

Last Update on Mar 30, 2023
Duke – Launch and Scale Speedometer
The Race for Global COVID-19 Vaccine Equity
See our COVID Vaccine Purchases research
See our COVID Vaccine Manufacturing research
See our COVID Vaccine Donations & Exports research

Overview of donations by top 10 donating countries
Bar chart is ordered by total number of doses pledged.
Donor charts are ordered by proportion of pledged donations shipped.

U.S.: COVID-19/Vaccines – Announcements/Regulatory Actions/Deployment

HHS
News
Fact Sheet: HHS Announces Intent to Amend the Declaration Under the PREP Act for Medical Countermeasures Against COVID-19
April 14, 2023 | News Release
Letter to U.S. Governors from HHS Secretary Xavier Becerra on renewing COVID-19 Public Health Emergency (PHE)
April 14, 2023 | News Release

HHS Office for Civil Rights Announces the Expiration of COVID-19 Public Health Emergency HIPAA Notifications of Enforcement Discretion
April 11, 2023 | News Release

FDA
Press Announcements
No new digest content identified.

FDA VRBPAC
Advisory Committee Calendar
Vaccines and Related Biological Products Advisory Committee May 18, 2023 Meeting Announcement - 05/18/2023
On May 18, 2023, the committee will meet in open session to discuss and make recommendations on the safety and effectiveness of ABRYSVO (Respiratory Syncytial Virus Vaccine), manufactured by Pfizer Inc., with a requested indication, in Biologics License Application (BLA) 125768 (STN 125768/0), for the prevention of lower respiratory tract disease and severe lower respiratory tract disease caused by RSV in infants from birth through 6 months of age by active immunization of pregnant individuals.

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency [EMA]
News & Press Releases
No new digest content identified.

European Centre for Disease Prevention and Control
https://www.ecdc.europa.eu/en
News/Updates/Reports [Selected]
News
WHO/ECDC report: antimicrobial resistance threatens patient safety in European Region
Press release - 14 Apr 2023

ECDC highlights measures to mitigate possible increase in mpox cases during spring and summer
Press release - 14 Apr 2023

Weekly COVID-19 country overview
Epidemiological update - 13 Apr 2023
Africa: COVID-19 – Announcements/Regulatory Actions/Deployment
https://africacdc.org/covid-19-vaccination/

Africa CDC COVID-19 Vaccine Dashboard
Safeguarding Africa's Health
Vaccine Overview Vaccination Coverage Vaccine Supply Vaccine Utilization Vaccine Policy Vaccine Delivery Targets
Member State Vaccine Summary

Vaccine Administration based on Eligible Population (Click to View Entire Population)

- **1101.8M** Vaccine Doses Received
- **1054.1M** Vaccine Doses Administered
- **95.7%** % Doses Utilized
- **49.9%** % Coverage (Fully Vaccinated)

(Last Update: March 23, 2023)

China: COVID-19/Vaccines – Announcements/Regulatory Actions/Deployment

National Medical Products Administration – PRC [to 15 Apr 2023]
http://english.nmpa.gov.cn/

News

**Top disease control body clarifies mask use**
2023-04-13
China's top disease control authorities clarified on Wednesday that people do not need to wear masks in outdoor spaces and workplaces, on campuses and when working out. The National Administration of Disease Prevention and Control released the latest mask use protocol on Wednesday evening, at a time when the waning COVID-19 epidemic has caused confusion among the public and different requirements from localities...

**Despite fewer cases, CDC reaffirms vaccination drive**
2023-04-11
Even though the COVID-19 pandemic is waning, people are still encouraged to get vaccinated and get their booster shots regardless of whether they have been previously infected or not, so as to reinforce herd immunity against the virus, Chinese authorities said on Monday.

At present, the domestic vaccination campaign is focused on bridging the gap in immunity levels across different populations and further reducing the risk of severe cases and deaths, according to a circular released by the State Council's Joint Prevention and Control Mechanism.
That means continuous efforts will be made to fully vaccinate people aged 3 to 17 and ensure that those aged 18 and above get a first booster shot and that vulnerable groups including the elderly and those with severe chronic diseases obtain a second booster shot.

It noted that people recently infected with COVID-19 need only wait three months before getting vaccinated. The previously recommended waiting period was six months.

The continuous optimization of the COVID-19 control strategy since November led to an epidemic wave that peaked in late December and infected at least 80 percent of the total population, according to the Chinese Center for Disease Control and Prevention...

-----

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
No new digest content identified. Last press release issued 31.08.2022.

-----

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Government of India – Press Information Bureau
Latest Press Releases
No new digest content identified.

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html
Press Releases
No new digest content identified.

Ministry of Health and Family Welfare
https://www.mohfw.gov.in/

COVID-19 (INDIA) as on: 15 April 2023, 03:30 IST ( GMT+5:30)
(†) Status change since yesterday

<p>| | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Active</strong></td>
<td><strong>Discharged</strong></td>
<td><strong>Deaths</strong></td>
<td></td>
</tr>
<tr>
<td>(0.12%)</td>
<td>(98.69%)</td>
<td>(1.19%)</td>
<td></td>
</tr>
<tr>
<td>53720</td>
<td>44223211</td>
<td>531091</td>
<td></td>
</tr>
</tbody>
</table>

COVID-19 Vaccination
as on: 15 April 2023, 00:00 IST ( GMT+5:30)

Total Vaccination: 220,66,25,517 (00,397 ↑)
**PHEIC**

**Mpxox**

*Public Health Emergency of International Concern (PHEIC)*

https://www.who.int/emergencies/situations/monkeypox-oubreak-2022

---

**Multi-country outbreak of mpxox, External situation report #20 -13 April 2023**

Highlights
- Since the last situation report published on 30 March 2023, 206 new mpxox cases (0.2% increase in total cases) and four new related deaths have been reported to WHO.
- Globally, the number of mpxox cases reported weekly continues to decline; however, the Western Pacific region is reporting an increase in the last few weeks, mainly driven by an outbreak with sustained local transmission in Japan.
- An mpxox cluster of 17 cases was reported in the Centre-Val del Loire region of France, and among them 10 (59%) are reported to have received two doses of vaccine.
- WHO is working to support Member States to control, and interrupt sustained person-to-person transmission of mpxox. This report contains discussion about the mpxox elimination strategies in the newly affected countries. Discussions about the possibility of global elimination are ongoing and WHO will support countries which choose to strive towards mpxox elimination, by establishing agreed global definitions and targets applicable to the different countries and settings.
- This report highlights WHO’s response in Europe across the objectives of the mpxox Strategic Preparedness, Readiness, and Response Plan

---

**PHEIC**

**Polio**

---

**Polio this week as of 11 April 2023 - GPEI**

Headlines [Selected]

No new digest content identified.

*Summary of new polioviruses this week:*
- Benin: one cVDPV2 case
- Burundi: three cVDPV2 positive environmental samples
- Democratic Republic of the Congo: one cVDPV1, six cVDPV2 cases and one cVDPV2 positive environmental sample.
- Somalia: one cVDPV2 positive environmental sample

---

**UN OCHA – Current Emergencies**

*Current Corporate Emergencies*  
**Afghanistan**
Editor’s Note:
We observe that OCHA has removed Afghanistan from its listing of “Current Emergencies.” We did not identify any explanation for its removal.

Northern Ethiopia
No new digest content identified.

Somalia
No new digest content identified.

Türkiye/Syria Earthquakes
14 Apr 2023
Today’s top news: Haiti, Malawi, Ukraine, Syria

Ukraine
Last Updated: 10 Feb 2023

WHO & Regional Offices [to 15 Apr 2023]
https://www.who.int/news
Selected News/Announcements/Statements
14 April 2023  Statement
Report of the meeting of the WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) held on 16-17 March 2023

14 April 2023  Departmental news
A brief overview of the Preparedness and Resilience for Emerging Threats initiative (PRET)

14 April 2023  Departmental news
World Chagas Disease Day 2023 to focus on integrating universal care and surveillance at the primary care level

13 April 2023  Departmental news
Join the global effort to enhance access to medicines and other health technologies: the 2nd World Local Production Forum to be held in the Kingdom of the Netherlands in 2023

13 April 2023  Departmental news
Highlighting a population’s health information needs during health emergencies through new infodemic management tools and frameworks

12 April 2023  Departmental news
WHO, African Union Development Agency, and the International Labour Organization join forces to safeguard health workers in Africa

11 April 2023  Departmental news
Improving access to novel COVID-19 treatments
**WHO Regional Offices**
Selected Press Releases, Announcements

**WHO African Region**
No new digest content identified.

**WHO Region of the Americas** PAHO
:: **New transatlantic partnership to address post-pandemic global health priorities and challenges**
   Arrangement between Pan American health Organization, World Health Organization Regional Office for Europe, and U.S. Department for Health and Human Services seeks to establish a more collaborative approach to strengthening health systems and services across regions.
:: **Strengthening primary care, harnessing new health technologies key to better pandemic recovery and preparedness, PAHO Director says**
   Washington, D.C., 13 April 2023 (PAHO) – Speaking at Global Health Summit Regional Meeting, the Director of the Pan American Health Organization (PAHO), Dr. Jarbas Barbosa, reiterated that collaboration, renewed attention to primary care and innovation will be key to bridge gaps in access to health and overcome inequalities painfully exposed...
:: **Less than 10% of people with Chagas receive a diagnosis**
   PAHO calls for first level of care to be strengthened to ensure early detection and treatment of disease that affects more than 6 million people globally, the vast majority in Latin America.
:: **Adequate health financing key to ensure resilient health systems, PAHO Director says**
   Washington D.C. 12 April 2023 – The Pan American Health Organization (PAHO) Director, Dr. Jarbas Barbosa, today called for greater investment in public health in the Americas to ensure health systems are better able to respond to the demands of a future emergency while maintaining essential services. The PAHO Director spoke at the Financing for...

**WHO South-East Asia Region** SEARO
No new digest content identified.

**WHO European Region** EURO
:: **14 April 2023** News release
**WHO/ECDC report: antimicrobial resistance threatens patient safety in European Region**
:: **14 April 2023** Media release
**New transatlantic partnership to address post-pandemic global health priorities and challenges**
:: **13 April 2023** News release
**WHO-supported emergency medical teams help thousands in Ukraine’s regained regions**

**WHO Western Pacific Region**
:: **11 April 2023**
**WHO delivers essential equipment and training to support whole genome sequencing in East M...**
:: **10 April 2023**
Strengthening local preparedness for influenza and COVID-19 in Cambodia

Disease Outbreak News (DONs)
Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

15 April 2023 | Marburg virus disease - Equatorial Guinea

11 April 2023 | Avian Influenza A(H3N8) - China

11 April 2023 | Pneumococcal meningitis - Togo

New WHO Publications
https://www.who.int/publications/i
Selected
14 April 2023
New recommendation on hepatitis C virus testing and treatment for people at ongoing risk of infection

14 April 2023
Recommended package of interventions for HIV, viral hepatitis and STI prevention, diagnosis, treatment...

11 April 2023
Guide for staff on engagement with non-State actors, second edition
Overview
The content of this guide is intended for internal use by WHO staff and is being made available for transparency purposes.

Engaging with non-State actors across the globe is essential for WHO to be able to achieve its goals and priorities and fulfil its critical mission. The Framework guides staff to maximize the benefits of these engagements, enhance non-State actors’ impact on health, and positively influence global stakeholders to better align with WHO’s norms, standards, and recommendations, in support of WHO Member States.

This guide is intended to help WHO staff at all levels of the Organization understand and apply the provisions in the Framework of Engagement with non-State actors (FENSA). It offers guidance on the modalities to consider when pursuing engagements with non-State actors.

11 April 2023
WHO policy brief: COVID-19 surveillance, 11 April 2023

:::...
U.S. STI Epidemic Showed No Signs of Slowing in 2021 – Cases Continued to Escalate

April 11, 2023  Reported cases of the sexually transmitted infections (STIs) chlamydia, gonorrhea, and syphilis all increased between 2020 and 2021 – reaching a total of more than 2.5 million reported cases – according to CDC’s final...

ACIP Meetings
Next ACIP Meeting:  June 21-22

MMWR Weekly
https://www.cdc.gov/mmwr/index2023.html
April 14, 2023 / No.15
PDF of this issue
- Secondary Cases of Invasive Disease Caused by Encapsulated and Nontypeable Haemophilus influenzae — 10 U.S. Jurisdictions, 2011–2018
- Update on Wild Poliovirus Type 1 Outbreak — Southeastern Africa, 2021–2022
- Racial and Ethnic Disparities in Mpox Cases and Vaccination Among Adult Males — United States, May–December 2022
- Epidemiologic and Clinical Features of Mpox-Associated Deaths — United States, May 10, 2022–March 7, 2023

Coronavirus Disease 2019 (COVID-19)- CDC
Announcements/reports/data summaries [Selected]
4/12/23
Overall US COVID-19 Vaccine Distribution and Administration Update as of Wed, 12 Apr 2023 06:00:00 EST

Africa CDC  [to 15 Apr 2023]
http://www.africacdc.org/
Press Releases
Impact Story
Africa CDC Saving Lives and Livelihoods Initiative in Partnership with Mastercard Foundation – Key Messages
12 April 2023
Key Messages
The Mastercard Foundation is deploying $1.5 billion in partnership with the Africa CDC to save the lives and livelihoods of millions of people in Africa, hastening the economic recovery of the continent.

This bold, partnership is ensuring vaccine equity for Africa by purchasing of vaccines for more than 65 million people, supporting the delivery of vaccinations to millions more, and integrating into and supporting the delivery of routine immunization ensuring the strengthening of public health systems in Africa.

The Saving Lives and Livelihoods initiative is assuring the long-term health security of the continent by developing the workforce for vaccine manufacturing in Africa and strengthening the Africa CDC.

This partnership is an enabler of and a contributor to the Foundation’s Young Africa Works strategy, which seeks to enable 30 million young people, particularly young women, to access dignified and fulfilling work by 2030.

---

**China CDC**
http://www.chinacdc.cn/en/

**National Health Commission of the People’s Republic of China** [to 15 Apr 2023]
http://en.nhc.gov.cn/
News
[Editor’s Note: The most recent post on this site is 24 Dec 2022, representing the last daily report on confirmed COVID-19 infections.]

**National Medical Products Administration – PRC** [to 15 Apr 2023]
http://english.nmpa.gov.cn/
News
*Top disease control body clarifies mask use*
2023-04-13

**China issues action plan to combat endemic diseases**
2023-04-12

**Despite fewer cases, CDC reaffirms vaccination drive**
2023-04-11

**China CDC Weekly Reports: Current Volume (5)**
2023-04-14 / No. 15  BREAST CANCER PREVENTION AND CONTROL ISSUE
View **PDF of this issue**

---

**Organization Announcements**

**Paul G. Allen Frontiers Group** [to 15 Apr 2023]
https://alleninstitute.org/news-press/
News
No new digest content identified.

BMGF - Gates Foundation  [to 15 Apr 2023]
https://www.gatesfoundation.org/ideas/media-center
Press Releases and Statements
No new digest content identified.

Bill & Melinda Gates Medical Research Institute  [to 15 Apr 2023]
https://www.gatesmri.org/news
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
News: Articles and Publications
No new digest content identified.

CARB-X  [to 15 Apr 2023]
https://carb-x.org/
No new digest content identified.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation  [to 15 Apr 2023]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Statements
:: Past weekly editions of Vaccines and Global Health: The Week in Review are available here.
:: Informed Consent: A Monthly Review – April 2023 is now posted here
:: Genomic Medicine – Governance, Ethics, Policy, Practice: A Monthly Digest – April 2023

CEPI – Coalition for Epidemic Preparedness Innovations  [to 15 Apr 2023]
http://cepi.net/
Latest News
No new digest content identified.

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES  [to 15 Apr 2023]
https://cioms.ch/
News; Publications; Events
Good Governance Practice for Research Institutions
PUBLIC CONSULTATION IS NOW OPEN
You are invited to comment on the below report by sending comments to ggpri@cioms.ch before 7 June 2023
Draft report: International Guidelines on Good Governance Practice for Research Institutions
Only comments on this form will be considered: download here

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 15 Apr 2023]
https://www.darpa.mil/news
News
No new digest content identified.

Duke Global Health Innovation Center [to 15 Apr 2023]
https://dukeghic.org/
Our Blog
No new digest content identified.

EDCTP [to 15 Apr 2023]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
News
No new digest content identified.

Emory Vaccine Center [to 15 Apr 2023]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

European Vaccine Initiative [to 15 Apr 2023]
http://www.euvaccine.eu/
Latest News, Events
News, Events
No new digest content identified.

Evidence Aid [to 15 Apr 2023]
Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.
http://www.evidenceaid.org/
Resources [Selected]
No new digest content identified.

Fondation Merieux [to 15 Apr 2023]
Gavi [to 15 Apr 2023]
https://www.gavi.org/
News Releases
13 April 2023
Gavi launches new learning initiative to address the final barriers to immunisation equity

GHIT Fund [to 15 Apr 2023]
https://www.ghitfund.org/newsroom/press
Press Releases
No new digest content identified.

Global Fund [to 15 Apr 2023]
News & Stories
No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 15 Apr 2023]
https://www.gloidr.org/news/
News
No new digest content identified.

Hilleman Laboratories [to 15 Apr 2023]
http://www.hilleman-labs.org/
News & Insights
No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 15 Apr 2023]
https://www.hhmi.org/news
Press Room
No new digest content identified.

Human Vaccines Project [to 15 Apr 2023]
http://www.humanvaccinesproject.org/
News
No new digest content identified.
**IAVI** [to 15 Apr 2023]
https://www.iavi.org/
*Latest News*
No new digest content identified.

**ICRC** [to 015 Oct 2022]
*What’s New  [Selected]*
**Facing the impact of climate change and armed conflict in the Near and Middle East**
A new ICRC/Norwegian Red Cross policy brief Making Adaptation Work presents how the humanitarian consequences of environmental degradation and climate change are aggravated by armed conflict in the Near and Middle East.
13-04-2023 | Report

**INSERM** [to 15 Apr 2023]
https://www.inserm.fr/en/home/
*Press Releases*
No new digest content identified.

**International Coalition of Medicines Regulatory Authorities [ICMRA]**
*Selected Statements, Press Releases, Research*
No new digest content identified.

**IFFIm**
http://www.iffim.org/
*Press Releases/Announcements*
No new digest content identified.

**IFRC** [to 15 Apr 2023]
*Press Releases [Selected]*
No new digest content identified.

**Institut Pasteur** [to 15 Apr 2023]
*Press Documents*
No new digest content identified.

**ISC / International Science Council** [to 15 Apr 2023]
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Latest Updates

Blogs

**Launch of the LIRA 2030 Africa reports highlighting key achievements and lessons learned from advancing transdisciplinary science in Africa**
03.04.2023

**International Union of Immunological Societies (IUIS)**
https://iuis.org/

*News/Events [Selected]*

**2023 International Day of Immunology**
Saturday 29th April 2023

The 2023 Day of Immunology theme is 'Immunology Talks to Public Health.' IUIS & EFIS invite all international societies to join in the effort to increase global awareness of the importance of immunology and demonstrate how our understanding of human immunology can improve public health.

*Read more about the Day of Immunology.*  
*REGISTER TODAY!*

**IVAC** [to 15 Apr 2023]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html

*Updates; Events*

*No new digest content identified.*

**IVI** [to 15 Apr 2023]
http://www.ivi.int/

*IVI News & Announcements*

*No new digest content identified.*

**Johns Hopkins Center for Health Security** [to 15 Apr 2023]
https://www.centerforhealthsecurity.org/news/center-news/

*Center News [Selected]*

*No new digest content identified.*

**MSF/Médecins Sans Frontières** [to 15 Apr 2023]
http://www.msf.org/

*Latest [Selected Announcements]*

**Philippines**

**Tackling tuberculosis in the slums of Manila**

Project Update  10 April 2023
National Academy of Medicine - USA [to 15 Apr 2023]
https://nam.edu/programs/
News [Selected]
No new digest content identified.

National Academy of Sciences - USA [to 15 Apr 2023]
News
Registration Now Open -- May 24-26 Nobel Prize Summit on Misinformation and Trust in Science
March 19, 2023
Registration is now open for the Nobel Prize Summit 'Truth Trust and Hope' a global conversation on how to stop misinformation from eroding public trust in science. Hosted by NAS and the Nobel Foundation the summit takes place May 24-26 in Washington D.C. and virtually.

National Vaccine Program Office - U.S. HHS [to 15 Apr 2023]
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
National Vaccine Advisory Committee (NVAC)
June 15-16, 2023 NVAC Meeting

NIH [to 15 Apr 2023]
http://www.nih.gov/
News Releases
No new digest content identified.

PATH [to 15 Apr 2023]
https://www.path.org/media-center/
Press Releases
PATH to become new host of the Global Nutrition Report
Published: April 2023
The Global Nutrition Report (GNR) is pleased to announce the appointment of PATH as its next host. The GNR is the world’s leading independent assessment of the state of global nutrition. It provides the best available data, in-depth analysis, and expert opinion rooted in evidence to help drive action on nutrition where it is urgently needed.

As a leading organization in global health, PATH has been selected for its extensive expertise in hosting initiatives, supporting partners, and driving action in nutrition. The organization was selected through a competitive tender process led by the GNR’s Independent Expert Group and Stakeholder Group...

Press Release
Additional panel of antibodies available to support the development of affordable pneumococcal vaccines
46 high-quality and affordable serotype-specific monoclonal antibodies (mAbs) now globally available to support the development of pneumococcal vaccines.

Published: April 2023

**Rockefeller Foundation** [to 15 Apr 2023]
https://www.rockefellerfoundation.org/
Selected Reports/Press Releases
Apr 11 2023 Press Releases
The Rockefeller Foundation Report Identifies Steps To Strengthen Global Food Crisis Response for More Resilient Food Systems
Report calls for approaches to build sustainable food and nutrition security and avert future crises.

**Sabin Vaccine Institute** [to 15 Apr 2023]
https://www.sabin.org/press/
Latest News & Press Releases
No new digest content identified.

**UNAIDS** [to 15 Apr 2023]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
Press release
A Triple Dividend: Fully financing the HIV response in Africa
Fully financing the HIV response to get back on track to achieve the 2030 goals will produce substantial health, social and economic gains in African countries. These findings are highlighted in a new report, A Triple Dividend: The health, social and economic gains from financing the HIV response in Africa
WASHINGTON DC/GENEVA, 12 April 2023

Press release
New UNAIDS Collaborating Center at Georgetown leverages strengths in HIV/AIDS law, policy and politics
WASHINGTON DC, 12 April 2023

**UNICEF** [to 15 Apr 2023]
https://www.unicef.org/media/press-releases
Latest press releases, news notes and statements
No new digest content identified.

**Unitaid** [to 15 Apr 2023]
https://unitaid.org/
Featured News
13 April 2023
Making Chagas a disease of the past by integrating it into primary health care
11 April 2023

**Improving access to novel COVID-19 treatments: Launch of Member States briefing on how to navigate interfaces between public health and intellectual property**

**Vaccine Equity Cooperative [nee Initiative]  [to 15 Apr 2023]**
https://vaccineequitycooperative.org/news/
News
No new digest content identified.

**Vaccination Acceptance & Demand Initiative [Sabin]  [to 15 Apr 2023]**
https://www.vaccineacceptance.org/
Announcements, Blog
2nd Annual Vaccination Acceptance Research Network Conference
VARN2023 Registration
Conference dates: June 13-15, 2023
Conference location: Bangkok, Thailand (venue information to come)

**Vaccine Confidence Project  [to 15 Apr 2023]**
http://www.vaccineconfidence.org/
News, Research and Reports
No new digest content identified.

**Vaccine Education Center – Children’s Hospital of Philadelphia  [to 15 Apr 2023]**
http://www.chop.edu/centers-programs/vaccine-education-center
No new digest content identified.

**Wellcome Trust  [to 15 Apr 2023]**
https://wellcome.ac.uk/news
News. Opinion, Reports
No new digest content identified.

**The Wistar Institute  [to 15 Apr 2023]**
Media
No new digest content identified.

**WFPHA: World Federation of Public Health Associations  [to 15 Apr 2023]**
https://www.wfpha.org/
Latest News - Blog
No new digest content identified.
**World Medical Association [WMA]**  [to 15 Apr 2023]
*Press Releases*
No new digest content identified.

**World Organisation for Animal Health (OIE)**  [to 15 Apr 2023]
https://www.oie.int/en/
*Press Releases, Statements*
*News*
**Global antimicrobial resistance forum launched to help tackle common threat to planetary health**
Published on 6 April 2023
The AMR Multi-Stakeholder Partnership Platform aims to address global antimicrobial resistance by bringing together voices from all countries and relevant sectors through a One Health approach.

ARM [Alliance for Regenerative Medicine]  [to 15 Apr 2023]
*Selected Press Releases*
**ARM Releases Statement on Texas Court Ruling Challenging the FDA**
April 13, 2023
Washington, DC
As the global voice of the cell and gene therapy sector, ARM believes courts lack the technical expertise to second-guess the FDA's scientific and medical judgment.

**BIO**  [to 15 Apr 2023]
*Press Releases*
**BIO JOINS AMICUS BRIEF CHALLENGING COURT’S EFFORTS TO UNDERMINE FDA’S AUTHORITY TO BRING TREATMENTS AND CURES TO PATIENTS**
April 11, 2023

**DCVMN – Developing Country Vaccine Manufacturers Network**  [to 15 Apr 2023]
http://www.dcvmn.org/
*News; Upcoming events*
No new digest content identified.

**ICBA – International Council of Biotechnology Associations**  [to 15 Apr 2023]
https://internationalbiotech.org/news/
*News*
No new digest content identified.
Top Pharma Leaders Meet with Japanese Officials to Discuss G7 Global Health Priorities and Strategic Dialogue for Life Science Growth in Japan

The CEOs presented the Tokyo Statement of the BCR to PM Kishida, which outlined top priorities for addressing global health challenges...

Save the date: 10th Global Patients Congress

We are delighted to announce that IAPO's 10th Global Patients Congress (GPC 2023) - "Innovative patient partnerships at the heart of global health advancement" will be held on 19 - 20 May 2023 at the Maison Internationale des Associations (MIA) in Geneva, Switzerland as a hybrid event.

PhRMA Files Amicus Brief with the U.S. Supreme Court in Support of FDA

WASHINGTON, D.C. (April 14, 2023) – The Pharmaceutical Research and Manufacturers of America (PhRMA) today filed an amicus brief with the U.S. Supreme Court in the U.S. Food and Drug Administration (FDA) v. Alliance for Hippocratic Medicine case.

Arguing in support of the FDA, the PhRMA brief supports the U.S. Fifth Circuit Court of Appeals’ (Fifth Circuit) decision to leave in place the 2000 FDA approval at issue in the district court. Importantly, the amicus brief also argues the Fifth Circuit should also have left in place the other challenged actions, including the 2016 FDA-approved changes to the relevant risk evaluation and mitigation strategy (REMS).

“Our brief aims to protect the FDA’s long-standing authority to determine whether a medicine is safe and effective for people to use, as Congress has authorized them to,” said Jim Stansel, who leads PhRMA’s legal and science and regulatory advocacy teams as Executive Vice President, General Counsel and Corporate Secretary...

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements
AstraZeneca
Press Releases

**ECCMID data reinforces AstraZeneca’s commitment to transform protection for the most vulnerable by advancing science in vaccines and immune therapies**

14 April 2023

AstraZeneca will highlight new data across its Vaccines and Immune Therapies portfolio at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), 15 – 18 April 2023, reinforcing its ambition to provide long-lasting immunity for millions of people globally. The company will present 15 abstracts, including four oral presentations, at the event.

Data featuring AZD3152, AstraZeneca’s investigational long-acting COVID-19 antibody, as well as Evusheld (tixagevimab and cilgavimab), Vaxzevria (ChAdOx1-S [Recombinant], formerly AZD1222) in COVID-19 and Beyfortus (nirsevimab) in respiratory syncytial virus (RSV) will be presented. Additional data on AstraZeneca’s growing vaccines and immune therapies pipeline against a variety of pathogens will also be presented. ..

Bharat Biotech
Press Releases - No new digest announcements identified

BioCubaFarma – Cuba
Últimas Noticias - Website not responding at inquiry

Biological E
News - No new digest announcements identified

BioNTech
Press Releases  - No new digest announcements identified

Boehringer
Press Releases  - No new digest announcements identified

CanSinoBIO
News - Website not responding at inquiry

CIGB
Latest News  - Website not responding at inquiry

Cinnagen
Recent News - No new digest announcements identified

Clover Biopharmaceuticals - China
News - No new digest announcements identified

Curevac [Bayer Ag – Germany]
News - No new digest announcements identified

Gamaleya National Center
Latest News and Events - See Russia above.
GSK
Press releases for media
15 April 2023
Gepotidacin’s positive phase III data shows potential to be the first in a new class of oral antibiotics for uncomplicated urinary tract infections in over 20 years
- Gepotidacin is a late-stage antibiotic in development in GSK’s growing infectious diseases portfolio

IMBCAMS, China
Home - Website not responding at inquiry

Janssen/JNJ
Press Releases - No new digest announcements identified

Merck
News releases - No new digest announcements identified

Moderna
Press Releases
11 April, 2023
Moderna Announces Clinical and Program Updates at 4th Vaccines Day
- Next-generation, refrigerator-stable COVID-19 vaccine candidate, mRNA-1283, has dosed first participant in its Phase 3 trial
- Company expects to file for approval of its investigational RSV vaccine candidate, mRNA-1345, this quarter
- Company's first influenza candidate, mRNA-1010, did not accrue sufficient cases at the interim efficacy analysis to declare early success in the Phase 3 Northern Hemisphere efficacy trial and the independent DSMB recommended continuation of efficacy follow-up
- Preliminary immunogenicity analysis from the Northern Hemisphere trial showed mRNA-1010 demonstrated titers consistent with superiority against influenza A strains (H1N1, H3N2) and non-inferiority against influenza B strains (B/Victoria, B/Yamagata) versus the licensed comparator
- Moderna announces new development candidates against Lyme disease, the Company's first bacterial vaccine, and norovirus, an enteric virus

Nanogen
News - No new digest announcements identified

Novartis
News - No new digest announcements identified

Novavax
Press Releases - No new digest announcements identified

Pfizer
Recent Press Releases - No new digest announcements identified

R-Pharm
https://rpharm-us.com/index.php
Serum Institute of India

NEWS & ANNOUNCEMENTS
Thursday, April 13, 2023

**R21/Matrix-M™ malaria vaccine developed by University of Oxford & SII receives regulatory clearance for use in Ghana**

The University of Oxford-developed and Serum Institute of India Pvt Ltd (SIIPL)- manufactured and scaled up R21/Matrix-M™ malaria vaccine, leveraging Novavax’s adjuvant technology, has been licensed for use in Ghana by the country’s Food and Drugs Authority.

Sinopharm/WIBPBP

News - No new digest announcements identified

Sinovac

Press Releases

**SINOVAC Launches New Influenza Vaccine Production Facility**

2023/04/10

Plant will expand worldwide flu vaccine capacity while setting leading standards for quality and sustainability

SK Biosciences

Press Releases - No new digest announcements identified

Takeda

Newsroom - No new digest announcements identified

Valneva

Press Releases - No new digest announcements identified

Vector State Research Centre of Viralogy and Biotechnology

Home - Website not responding [404 error]

WestVac Biopharma

Media - No new digest announcements identified

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[No website identified]
Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics
Volume 14, 2023 Issue 1
https://www.tandfonline.com/toc/uabr21/current
[Reviewed earlier]

AMA Journal of Ethics
Volume 25, Number 4: E239-304 April 2023
https://journalofethics.ama-assn.org/issue/clinicians-government

Meat and Health
As meat production and consumption increase globally, so do incidences of diet-related illnesses, such as coronary artery disease and obesity. Some meat industry practices undermine public and environmental health, both of which clinicians, health professions, health care organizations, and governments are duty-bound to promote. This issue considers the nature and scope of these groups’ obligations to mitigate negative influences of nonhuman animal production and consumption on health in individual, community, domestic, and international spheres.

American Journal of Infection Control
April 2023 Volume 51 Issue 4 p361-480
http://www.ajicjournal.org/current
[Reviewed earlier]

American Journal of Preventive Medicine
April 2023 Volume 64 Issue 4 p459-610
https://www.ajpmonline.org/current
[Reviewed earlier]
Explainable AI tools for legal reasoning about cases: A study on the European Court of Human Rights
Joe Collenette, Katie Atkinson, Trevor Bench-Capon
Article 103861

Abstract
In this paper we report on a significant research project undertaken to design, implement and evaluate explainable decision-support tools for deciding legal cases. We provide a model of a legal domain, Article 6 of the European Convention on Human Rights, constructed using a methodology from the field of computational models of argument. We describe how the formal model has been developed, extended and transformed into practical tools, which were then used in evaluation exercises to determine the effectiveness and usability of the tools. The underpinning AI techniques used yield a level of explanation that is firmly grounded in legal reasoning and is also digestible by the target end users, as demonstrated through our evaluation activities. The results of our experimental evaluation show that on the first pass, our tool achieved an accuracy rate of 97% in matching the actual decisions of the cases and the user studies conducted gave highly encouraging results with respect to usability. As such, our project demonstrates how trustworthy AI tools can be built for a real world legal domain where critical needs of the end users are accounted for.
Editorial
Demographic trends and population health: tackling inequality in a world of eight billion people (4 April, 2023)
Thoai D Ngo

Original research
Emergent patterns in global health diplomacy: a network analysis of the resolutions adopted by the World Health Assembly from 1948 to 2022 (6 April, 2023)
Didier Wernli, Jean-Luc Falcone, Stephan Davidshofer, Kelley Lee, Bastien Chopard, Nicolas Levrat

Practice
How international research consortia can strengthen organisations’ research systems and promote a conducive environment and culture (7 April, 2023)
Justin Pulford, Taghreet El Hajj, Tara Tancred, Yan Ding, Susie Crossman, Lorelei Silvester, Martina Savio, Natasha Bevan, Nadia Tagoe, Imelda Bates

BMC Health Services Research
http://www.biomedcentral.com/bmchealthservres/content
(Accessed 15 Apr 2023)
Associations between the stringency of COVID-19 containment policies and health service disruptions in 10 countries
Disruptions in essential health services during the COVID-19 pandemic have been reported in several countries. Yet, patterns in health service disruption according to country responses remain unclear. In this ...
Authors: Tarylee Reddy, Neena R. Kapoor, Shogo Kubota, Svetlana V Doubova, Daisuke Asai, Damen Haile Mariam, Wondimu Ayele, Anagaw Derseh Mebratie, Roody Thermidor, Jaime C. Sapag, Paula Bedregal, Álvaro Passi-Solar, Georgiana Gordon-Strachan, Mahesh Dulal, Dominic Dormenyo Gadeka, Suresh Mehata...
Citation: BMC Health Services Research 2023 23:363
Content type: Research Published on: 12 April 2023

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 15 Apr 2023)
Influenza vaccine uptake among children and older adults in China: a secondary analysis of a quasi-experimental study
Influenza vaccination is the key to prevent influenza-related disease, especially among high-risk populations. However, influenza vaccine uptake in China is low. This secondary analysis of a quasi-experimental...
Authors: Yumeng Du, Chenqi Jin, Mark Jit, Tracey Chantler, Leesa Lin, Heidi J. Larson, Jing Li, Wenfeng Gong, Fan Yang, Nina Ren, Weibin Cheng, Yi Zhou, Weiming Tang, Joseph D. Tucker and Dan Wu
Citation: BMC Infectious Diseases 2023 23:225
Content type: Research Published on: 13 April 2023
Previous BCG vaccination is associated with less severe clinical progression of COVID-19

BCG vaccination, originally used to prevent tuberculosis, is known to “train” the immune system to improve defence against viral respiratory infections. We investigated whether a previous BCG vaccination is as...

Authors: Susan Martins Pereira, Florisneid Rodrigues Barreto, Ramon Andrade de Souza, Carlos Antonio de Souza Teles Santos, Marcos Pereira, Enny Santos da Paixão, Carla Cristina Oliveira de Jesus Lima, Marcio Santos da Natividade, Ana Angélica Bulcão Portela Lindoso, Eder Gatti Fernandes, Evonio Barros Campelo Junior, Julia Moreira Pescarini, Kaio Vinicius Freitas de Andrade, Fernanda Mattos de Souza, Elisangela Alves de Britto, Ceuci Nunes...

Citation: BMC Medicine 2023 21:145
Content type: Research article Published on: 13 April 2023

Considerable doubt about rubella screening and vaccination among unvaccinated orthodox protestant women: a mixed-methods study

Women who are susceptible to rubella are advised to vaccinate against rubella to prevent infection in future pregnancies, and thus avert the risk of congenital rubella syndrome in their unborn child.

Rubella o...

Authors: Anne C. de Munter, Jeannine L. A. Hautvast, Wilhelmina L. M. Ruijs, Robert A. C. Ruiter and Marlies E. J. L. Hulscher

Citation: BMC Public Health 2023 23:693
Content type: Research Published on: 14 April 2023

The association of conspiracy beliefs and the uptake of COVID-19 vaccination: a cross-sectional study

The COVID-19 pandemic revealed that health denialism might be an important determinant of adherence to preventive measures during epidemic challenges. Conspiracy beliefs seem to be one of the most visible mani...

Authors: Kinga Kowalska-Duplaga and Mariusz Duplaga

Citation: BMC Public Health 2023 23:672
Decades of oncologic clinical use have demonstrated that cancer immunotherapy provides unprecedented therapeutic benefits. Tragically, only a minority of patients respond to existing immunotherapies. RNA lipid nanoparticles have recently emerged as modular tools for immune stimulation. Here, we discuss advancements in RNA-based cancer immunotherapies and opportunities for improvement.
Current Protocols in Human Genetics
Volume 108, Issue 1  December 2020
https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current
[Reviewed earlier]

Developing World Bioethics
Volume 23, Issue 1  Pages: 1-87  March 2023
https://onlinelibrary.wiley.com/toc/14718847/current
[Reviewed earlier]

Development in Practice
Volume 33, Issue 1, 2023
http://www.tandfonline.com/toc/cdip20/current
[Reviewed earlier]

Development Policy Review
Volume 41, Issue 2  March 2023
https://onlinelibrary.wiley.com/toc/14677679/current
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness
Volume 16 - Issue 6 - December 2022
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue
[Reviewed earlier]

Disasters
Volume 47, Issue 2  Pages: 245-542  April 2023
https://onlinelibrary.wiley.com/toc/14677717/2023/47/2
[Reviewed earlier]

EMBO Reports
Volume 24  Issue 4  5 April 2023
https://www.embopress.org/toc/14693178/current
[New issue; No digest content identified]

Emerging Infectious Diseases
Epidemics
Volume 42  March 2023
[Reviewed earlier]

Epidemiology and Infection
Volume 151 - 2023
https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue
[Reviewed earlier]

Ethics & Human Research
Volume 45, Issue 2  Pages: 1-42  March–April 2023
https://onlinelibrary.wiley.com/toc/25782363/current
:: Conflicts of interest :: Surrogate consent and decisional impairment
[Reviewed earlier]

Ethics & International Affairs
Winter 2022 (36.4)  December 21, 2022
[Reviewed earlier]

Ethics, Medicine and Public Health
Volume 27  April 2023
[Reviewed earlier]

The European Journal of Public Health
Volume 33, Issue 2, April 2023
https://academic.oup.com/eurpub/issue/33/2
[Reviewed earlier]

Expert Review of Vaccines
Vol 22 (1) 2023  Issue In Progress
https://www.tandfonline.com/toc/ierv20/current
[Reviewed earlier]
Foreign Affairs
Volume 102, Number 1  January/February 2023
https://www.foreignaffairs.com/issues/2023/102/1
[No new digest content identified]

Forum for Development Studies
Volume 50, 2023 - Issue 1
http://www.tandfonline.com/toc/sfds20/current
[Reviewed earlier]

Genetics in Medicines
Volume 25, Issue 4  April 2023
[Reviewed earlier]

Genome Medicine
https://genomemedicine.biomedcentral.com/articles
[Accessed 15 Apr 2023]
[No new digest content identified]

Global Health Action
Volume 16, Issue 1 (2023)
https://www.tandfonline.com/toc/zgha20/current?nav=tocList
[Reviewed earlier]

Global Health: Science and Practice (GHSP)
Vol. 11, No. 1  February 28, 2023
http://www.ghspjournal.org/content/current
[Reviewed earlier]

Global Legal Monitor – Library of Congress/USA
https://www.loc.gov/collections/global-legal-monitor/
[Accessed 15 Apr 2023]
[No new digest content identified]

Global Public Health
Volume 18, Issue 1 (2023)
http://www.tandfonline.com/toc/rgph20/current
[Reviewed earlier]
Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 15 Apr 2023]
[No new digest content identified]

Health and Human Rights
Volume 24, Issue 2, December 2022
Special Section: COVID-19 Vaccine Equity and Human Rights
[Reviewed earlier]

Health Economics, Policy and Law
Volume 18 - Issue 2 - April 2023
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue
[Reviewed earlier]

Health Policy and Planning
Volume 38, Issue 3, April 2023
https://academic.oup.com/heapol/issue/38/3
ORIGINAL ARTICLES
[Reviewed earlier]

Health Research Policy and Systems
http://www.health-policy-systems.com/content
[Accessed 15 Apr 2023]
[No new digest content identified]

Human Gene Therapy
Volume 34, Issue 5-6 / March 2023
https://www.liebertpub.com/toc/hum/34/5-6
[Reviewed earlier]

Humanitarian Practice Network
https://odihpn.org/
Featured Publications
[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 18, Issue 5, 2022
https://www.tandfonline.com/toc/khvi20/18/5?nav=tocList
[Reviewed earlier]
[Reviewed earlier]

**JAMA**
April 11, 2023, Vol 329, No. 14, Pages 1133-1232
https://jamanetwork.com/journals/jama/currentissue
[New issue; No digest content identified]

**JAMA Health Forum**
April 2023, Vol 4, No. 4
https://jamanetwork.com/journals/jama-health-forum/issue
[Reviewed earlier]

**JAMA Pediatrics**
April 2023, Vol 177, No. 4, Pages 327-441
https://jamanetwork.com/journals/jamapediatrics/currentissue
[Reviewed earlier]

**JBI Evidence Synthesis**
March 2023 - Volume 21 - Issue 3
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx
[Reviewed earlier]

**Journal of Adolescent Health**
April 2023 Volume 72 Issue 4 p485-646
https://www.jahonline.org/current
[Reviewed earlier]

**Journal of Artificial Intelligence Research**
Vol. 76 (2023)
https://www.jair.org/index.php/jair
Contents
[Reviewed earlier]

**Journal of Community Health**
Volume 48, issue 1, February 2023
https://link.springer.com/journal/10900/volumes-and-issues/48-1
[Reviewed earlier]

**Journal of Current Medical Research and Opinion**
...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.
March 8, 2023  Vol 6, No 03 (2023)
https://www.cmro.in/index.php/jcmro/issue/view/65
[Reviewed earlier]

Journal of Development Economics
Volume 162  May 2023
[New issue; No digest content identified]

Journal of Empirical Research on Human Research Ethics
Volume 18 Issue 1-2, February-April 2023
http://journals.sagepub.com/toc/jre/current
[Reviewed earlier]

Journal of Epidemiology & Community Health
March 2023 - Volume 77 - 3
https://jech.bmj.com/content/77/3
[Reviewed earlier]

Journal of Evidence-Based Medicine
Volume 16, Issue 1  Pages: 1-100  March 2023
https://onlinelibrary.wiley.com/toc/17565391/current
[New issue; No digest content identified]

Journal of Global Ethics
Volume 18, Issue 3, 2022
http://www.tandfonline.com/toc/rjge20/current
[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 34, Number 1, February 2023
https://muse.jhu.edu/issue/49033
Table of Contents
[Reviewed earlier]

Journal of Immigrant and Minority Health
Volume 25, issue 1, February 2023
Journal of Immigrant & Refugee Studies
Volume 21, 2023 Issue 1
https://www.tandfonline.com/toc/wimm20/current
[Reviewed earlier]

Journal of Infectious Diseases
Volume 227, Issue 7, 1 April 2023
https://academic.oup.com/jid/issue/227/7
[New issue; No digest content identified]

Journal of International Development
Volume 35, Issue 2 Pages: 199-381 March 2023
https://onlinelibrary.wiley.com/toc/10991328/current
[Reviewed earlier]

Journal of Medical Ethics
April 2023 - Volume 49 - 4
http://jme.bmj.com/content/current
[Reviewed earlier]

Journal of Patient-Centered Research and Reviews
Volume 10, Issue 1 (2023)
https://institutionalrepository.aah.org/jpcrr/
[Reviewed earlier]

Journal of Pediatrics
March 2023 Volume 254 p1-106
http://www.jpeds.com/current
[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[Accessed 15 Apr 2023]
Vaccine cold chain management practice and associated factors among health professionals in Ethiopia: systematic review and meta-analysis
Authors: Abebaw Wasie Kasahun, Amare Zewdie, Solomon Shitu and Girma Alemayehu
Content type: Review 12 April 2023
Journal of Public Health Management & Practice  
May/June 2023 - Volume 29 - Issue 3  
https://journals.lww.com/jphmp/pages/currenttoc.aspx  
[Reviewed earlier]

Journal of Public Health Policy  
Volume 44, issue 1, March 2023  
https://link.springer.com/journal/41271/volumes-and-issues/44-1  
**Articles**  
**The obligation to use face masks in public spaces as a public health measure and permissible limits on civil liberties**  
Authors  
Anna Garus-Pakowska  
Maciej Pakowski  
Content type: Viewpoint  
Published: 11 March 2023  
Pages: 110 - 121

**Integrated approaches to COVID-19 emergency response in fragile, conflict-affected and vulnerable settings: a public health policy brief**  
Authors (first, second and last of 5)  
Olushayo Oluseun Olu  
Joy Luba Lomole Waya  
Argata Guracha Guyo  
Content type: Viewpoint  
Open Access  
Published: 23 December 2022  
Pages: 122 - 137

Journal of Refugee & Global Health  
Volume 4, Issue 1 (2021)  
https://ir.library.louisville.edu/rgh/  
[Reviewed earlier]

Journal of the Royal Society – Interface  
April 2023 Volume 20 Issue 201  
https://royalsocietypublishing.org/toc/rsif/current  
[Reviewed earlier]

Journal of Travel Medicine  
Volume 30, Issue 2, March 2023  
https://academic.oup.com/jtm/issue  
Systematic Reviews
Editor's Choice

Yellow fever vaccine safety in immunocompromised individuals: a systematic review and meta-analysis
Leticia Wigg de Araújo Lagos, MSc, Ariane de Jesus Lopes de Abreu, MSc, Rosângela Caetano, DSc, José Ueleres Braga, DSc

Research Letter

A nationwide prospective cohort study on safety of the 17D-204 yellow fever vaccine during a vaccine shortage in Japan
Yusuke Miyazato, MD, Mari Terada, MPH, Mugen Ujiie, MD, MTM, PhD, Sho Saito, MD, Akinari Moriya, MD ...
Journal of Travel Medicine, Volume 30, Issue 2, March 2023, taac070, https://doi.org/10.1093/jtm/taac070

In response to the vaccine shortage of yellow fever vaccine (YF-VAX) due to manufacturing delays, the unapproved 17D-204 YF-VAX was used as an investigator-initiated clinical trial in Japan. The vaccine was administered to 11,279 participants in 19 YF vaccination centres in Japan, and few serious adverse events were observed.

Journal of Virology
Volume 97 Number 3 March 2023
http://jvi.asm.org/content/current

Bacteriology Editorial
27 February 2023
Oversight of Pathogen Research Must Be Carefully Calibrated and Clearly Defined
Anice C. Lowen, et al.
https://doi.org/10.1128/jvi.00176-23

By providing consultation to the United States Government (USG) on matters of biosecurity, the National Science Advisory Board for Biosecurity (NSABB) plays a critical role in ensuring the safety of biomedical research in the United States.

Vaccines Commentary
14 March 2023
The Failure of AIDS Vaccine Efficacy Trials: Where to Go from Here
Ronald C. Desrosiers
https://doi.org/10.1128/jvi.00211-23

The seven AIDS vaccine efficacy trials have yielded extremely disappointing results at great expense. Greater stringency is needed for government support of AIDS vaccine efficacy trials.

The Lancet
Apr 15, 2023 Volume 401 Number 10384 p1241-1312, e20
https://www.thelancet.com/journals/lancet/issue/current
[New issue; No digest content identified]
Editorial

Advancing the rights of street and working children
The Lancet Child & Adolescent Health

Articles

Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3–17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial
Lidong Gao, et al.

Lancet Digital Health
Apr 2023 Volume 5 Number 4 e174-e247
https://www.thelancet.com/journals/landig/issue/current

Editorial

Wearable health data privacy
The Lancet Digital Health

Articles

Paediatric safety assessment of BNT162b2 vaccination in a multistate hospital-based electronic health record system in the USA: a retrospective analysis
Robert P Matson, et al.

Review

Does deidentification of data from wearable devices give us a false sense of security? A systematic review
Lucy Chikwetu, et al.

Lancet Global Health
May 2023 Volume 11 Number 5 e629-e795
https://www.thelancet.com/journals/langlo/issue/current

Articles

Ledor S Igboh, et al.

Impact of proactive and reactive vaccination strategies for health-care workers against MERS-CoV: a mathematical modelling study
Daniel J Laydon, et al.

Viewpoint

A global aircraft-based wastewater genomic surveillance network for early warning of future pandemics
Jiaying Li, et al.
**Lancet Infectious Diseases**

Apr 2023 Volume 23 Number 4 p381-508, e121-e165
https://www.thelancet.com/journals/laninf/issue/current

*Articles*

**Viral dynamics in patients with monkeypox infection: a prospective cohort study in Spain**
Clara Suñer, et al.

**The global landscape of smallpox vaccination history and implications for current and future orthopoxvirus susceptibility: a modelling study**
Juliana C Taube, et al.

---

**Lancet Public Health**

Apr 2023 Volume 8 Number 4 e247-e317
https://www.thelancet.com/journals/lanpub/issue/current

*Editorial*

**Taking tuberculosis out of the shadows**
The Lancet Public Health

... On Sept 22, 2023, the second UN High-Level Meeting on the fight against tuberculosis will be held. This will bring together heads of state worldwide and offer the opportunity for a strong political declaration to end tuberculosis, with a focus on scientific innovation and funding. The COVID-19 pandemic has inspired several innovative approaches to tackle tuberculosis, such as the implementation of digital interventions using video-supported telemonitoring to ensure treatment adherence and changes improving longer-term access to drugs. Another step in the right direction is the establishment of a new WHO TB Vaccine Accelerator Council with the aim to drive innovation in the area of tuberculosis vaccines. However, research and development for COVID-19 was also supported with a much larger budget. In 2020, more than US$100 billion were mobilised for research and development for COVID-19 and only $0·9 billion for tuberculosis.

The upcoming UN High-Level Meeting should be a tremendous opportunity to reinvigorate the fight against tuberculosis and the political will to fund tuberculosis elimination and tackle its key modifiable risk factors—marginalisation and social inequality. Tuberculosis is the pinnacle of the social determinants of health. Yes, we can end tuberculosis—with strong political will, adequate funding, and an unambiguous commitment to address inequalities, the underlying determinant of tuberculosis.

*Viewpoint*

**Scaling up evidence-based approaches to tuberculosis screening in prisons**
Salome Charalambous, et al.

**Effectiveness assessment of non-pharmaceutical interventions: lessons learned from the COVID-19 pandemic**
Adrian Lison, et al.

---

**Lancet Respiratory Medicine**

Apr 2023 Volume 11 Number 4 p297-390, e31-e40
https://www.thelancet.com/journals/lanres/issue/current

*Editorial*

**Time to invest in tuberculosis research and disease control**
Advances in tuberculosis control during the past decade
Kogieleum Naidoo, Rubeshan Perumal

Clinical trials of tuberculosis vaccines in the era of increased access to preventive antibiotic treatment
Molebogeng X Rangaka, et al.

Maternal and Child Health Journal
Volume 27, issue 2, February 2023
[Reviewed earlier]

Medical Decision Making (MDM)
Volume 43 Issue 3, April 2023
http://mdm.sagepub.com/content/current
[Reviewed earlier]

The Milbank Quarterly
A Multidisciplinary Journal of Population Health and Health Policy
Volume 101, Issue 1 Pages: 1-248 March 2023
https://onlinelibrary.wiley.com/toc/14680009/current
[Reviewed earlier]

Nature
Volume 616 Issue 7956, 13 April 2023
https://www.nature.com/nature/volumes/616/issues/7956
Perspective 12 Apr 2023
Foundation models for generalist medical artificial intelligence
This review discusses generalist medical artificial intelligence, identifying potential applications and setting out specific technical capabilities and training datasets necessary to enable them, as well as highlighting challenges to its implementation.
Michael Moor, Oishi Banerjee, Pranav Rajpurkar

Nature Biotechnology
Volume 41 Issue 3, March 2023
https://www.nature.com/nbt/volumes/41/issues/3
[Reviewed earlier]
The Allis code
David Allis (1951–2023) was a leading figure in the field of chromatin biology. He inspired many generations of scientists both through his work and his own personal example as a mentor and colleague. His influential ‘histone code’ theory remains an important guiding principle to study and understand gene regulation.

A manifesto for applying behavioural science
Behavioural science is increasingly used in the public and private sectors, but it has been subject to several criticisms. This Perspective proposes a manifesto for behavioural science, addressing these criticisms and describing a way forward for the field.
Michael Hallsworth

Strategic recommendations from the STARS project to foster academic drug development
Improved understanding of regulatory requirements by academic researchers can accelerate the translation of new medical interventions to the clinic. Here, we highlight the recommendations of the ‘Strengthening Training of Academia in Regulatory Science’ (STARS) project to improve the interaction and knowledge exchange between academics and regulators, and thereby advance academic drug development.
Viktoriia Starokozhko, et al.

Perspective 13 Feb 2023
The evolving role of investigative toxicology in the pharmaceutical industry
Investigative toxicology tools and strategies are used in pharmaceutical companies to reduce safety-related attrition in drug development. This Perspective article summarizes the key goals of investigative toxicology, highlights current approaches and discusses selected emerging technologies that have the potential to improve the current safety-testing paradigm.
Francois Pognan, et al.

Nature Reviews Genetics
Volume 24 Issue 4, April 2023
https://www.nature.com/nrg/volumes/24/issues/4
Comment 13 Jan 2023

Prioritizing the detection of rare pathogenic variants in population screening
Lacaze et al. caution against the use of polygenic scores alone for population screening in the absence of monogenic testing.
Paul Lacaze, et al.

Nature Reviews Immunology
Volume 23 Issue 3, March 2023
https://www.nature.com/nri/volumes/23/issues/3
[Reviewed earlier]

New England Journal of Medicine
April 13, 2023  Vol. 388 No. 15
https://www.nejm.org/toc/nejm/medical-journal
Editorial
Audio Interview: When to Get a Second Covid-19 Booster Shot
E.J. Rubin, L.R. Baden, and S. Morrisseye

npj Vaccines
https://www.nature.com/npjvaccines/
[Accessed 15 Apr 2023]
Perspective Open Access
Published: 15 April 2023
Is new dengue vaccine efficacy data a relief or cause for concern?
Stephen J. Thomas
Abstract
Dengue is a major global public health problem requiring a safe and efficacious vaccine as the foundation of a comprehensive countermeasure strategy. Despite decades of attempts, the world has a single dengue vaccine licensed in numerous countries, but restrictions and conditions of its use have deterred uptake. Recently, clinical efficacy data has been revealed for two additional dengue vaccine candidates and the data appears encouraging. In this perspective I discuss dengue, the complexities of dengue vaccine development, early development setbacks, and how the latest data from the field may be cause for measured optimism. Finally, I provide some perspectives on evaluating dengue vaccine
performance and how the pursuit of the perfect dengue vaccine may prevent advancement of vaccines which are good enough.

Meeting Report  Open Access
Published: 12 April 2023
Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities—workshop report
On November 7th and 8th, 2022, The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), The Coalition for Epidemic Preparedness Innovation (CEPI), The Bill & Melinda Gates Foundation (BMGF), The Biomedical Advanced Research and Development Authority (BARDA), and the Wellcome Trust hosted a virtual workshop entitled “Mucosal Vaccines for SARS-CoV-2: Scientific Gaps and Opportunities.” During the workshop, researchers and vaccine developers from around the world discussed the potential of mucosal vaccines to block SARS-CoV-2 transmission and reviewed the status of SARS-CoV-2 mucosal vaccine research. Here, we summarize key challenges and opportunities in basic, translational, and clinical research that were highlighted during the meeting. We also provide recommendations to advance the field and accelerate the development of mucosal vaccines for SARS-CoV-2.
Jane M. Knisely, et al.

Pediatrics
Volume 151, Issue 4  April 2023
https://publications.aap.org/pediatrics/issue/151/4
[Reviewed earlier]

PharmacoEconomics
Volume 41, issue 3, March 2023
[Reviewed earlier]

PLoS Biology
https://journals.plos.org/plosbiology/
(Accessed 15 Apr 2023)
[No new digest content identified]

PLoS Genetics
https://journals.plos.org/plosgenetics/
(Accessed 15 Apr 2023)
[No new digest content identified]

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 15 Apr 2023)
Mental disorders and COVID-19 deaths: Clinical, public health, and human rights implications
The COVID-19 pandemic and health-related quality of life across 13 high- and low-middle-income countries: A cross-sectional analysis
Mara Violato, Jack Pollard, Andrew Lloyd, Laurence S. J. Roope, Raymond Duch, Matias Fuentes Becerra, Philip M. Clarke
Research Article | published 11 Apr 2023 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1004220

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 15 Apr 2023)
[No new digest content identified]

PLoS One
http://www.plosone.org/
[Accessed 15 Apr 2023]
Understanding the barriers and facilitators of vaccine hesitancy towards the COVID-19 vaccine in healthcare workers and healthcare students worldwide: An Umbrella Review
Jemma Louise McCready, Bethany Nichol, Mary Steen, John Unsworth, Dania Compacini, Marco Tomietto
Research Article | published 12 Apr 2023 PLOS ONE
https://doi.org/10.1371/journal.pone.0280439

PLoS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 15 Apr 2023]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States
April 11, 2023 vol. 120 no. 15
https://www.pnas.org/toc/pnas/120/15
Brief Report April 5, 2023
Political ideology and generosity around the globe
Abstract
In a world severely put under stress by COVID-19, generosity becomes increasingly essential both when able to transcend local boundaries, building upon universalistic values, and when directed toward more local contexts, such as the native country. This study aims to investigate an underresearched determinant of generosity at these two levels, a factor that captures one’s beliefs, values, and opinions about society: political ideology. We study the donation decisions of more than 46,000 participants from 68 countries in a task with the possibility of donating to a national charity and an international one. We test whether more left-leaning individuals display higher generosity in general (H1) and
toward international charities (H2). We also examine the association between political ideology and national generosity without hypothesizing any direction. We find that more left-leaning individuals are more likely to donate in general and more likely to be generous internationally. We also observe that more right-leaning individuals are more likely to donate nationally. These results are robust to the inclusion of several controls. In addition, we address a relevant source of cross-country variation, the quality of governance, which is found to have significant informative power in explaining the relationship between political ideology and the different types of generosity. Potential mechanisms underlying the resulting behaviors are discussed.

Veronica Pizziol, Xhiselda Demaj, [...] Valerio Capraro

**PNAS Nexus**
Volume 2, Issue 3, March 2023
IN PROGRESS
https://academic.oup.com/pnasnexus/issue
[Reviewed earlier]

**Prehospital & Disaster Medicine**
Volume 38 - Issue 2 - April 2023
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue
[Reviewed earlier]

**Preventive Medicine**
Volume 168  March 2023
[Reviewed earlier]

**Proceedings of the Royal Society B**
12 April 2023  Volume 290  Issue 1996
https://royalsocietypublishing.org/toc/rspb/current
[New issue; No digest content identified]

**Public Health**
Volume 217  Pages 1-218 (April 2023)
[Reviewed earlier]

**Public Health Ethics**
Volume 15, Issue 3, November 2022
http://phe.oxfordjournals.org/content/current
[Reviewed earlier]
Public Health Reports
Volume 138 Issue 2, March/April 2023
https://journals.sagepub.com/toc/phrg/138/2
[Reviewed earlier]

Qualitative Health Research
Volume 33 Issue 4, March 2023
https://journals.sagepub.com/toc/qhra/current
[Reviewed earlier]

Research Ethics
Volume 19 Issue 2, April 2023
http://journals.sagepub.com/toc/reab/current
[Reviewed earlier]

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 15 Apr 2023]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en
Selected Articles
14 Apr 2023
Cost of lost productivity from acute respiratory infections in South America
Original research | English |

14 Apr 2023
Validation of COVID-19 vaccines administered abroad: experience and challenges of implementation in Chile
Current topic |

14 Apr 2023
Influenza A(H3N2) infection followed by separate COVID-19 infection
Brief communication | English |

Risk Analysis
Volume 43, Issue 3 Pages: 429-643 March 2023
https://onlinelibrary.wiley.com/toc/15396924/current
[Reviewed earlier]
Science
Volume 380| Issue 6641| 14 Apr 2023
https://www.science.org/toc/science/current

Human reproduction - Introduction to Special Issue
Reproductive medicine
BY Yevgeniya Nusinovich
13 Apr 2023: 148-149

Policy Forum
Rethink reporting of evaluation results in AI
BY Ryan Burnell, et al.
13 Apr 2023: 136-138
Aggregate metrics and lack of access to results limit understanding

Science and Engineering Ethics
Volume 29, issue 1, February 2023
https://link.springer.com/journal/11948/volumes-and-issues/29-1
[Reviewed earlier]

Science Translational Medicine
Volume 15| Issue 691| 12 Apr 2023
https://www.science.org/toc/stm/current
[New issue; No digest content identified]

Social Science & Medicine
Volume 320  March 2023
[Reviewed earlier]

Systematic Reviews
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 15 Apr 2023]
[No new digest content identified]

Theoretical Medicine and Bioethics
Volume 44,  April 2023, Issue 2
Special Issue: Controversial Arguments in Bioethics

Travel Medicine and Infectious Diseases
Volume 52  March–April 2023
[Reviewed earlier]

Tropical Medicine & International Health
Volume 28, Issue 4  Pages: i-iv, 247-342  April 2023
https://onlinelibrary.wiley.com/toc/13653156/current
[Reviewed earlier]

Vaccine
Volume 41, Issue 13  Pages 2101-2316 (24 March 2023)
https://www.sciencedirect.com/journal/vaccine/vol/41/issue/13
Selected Content
Review article  Open access
A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy
Kristine A. Moore, Tabitha Leighton, Julia T. Ostrowsky, Cory J. Anderson, ... Michael T. Osterholm
Pages 2101-2112

Research article  Full text access
The effects of parent's health literacy and health beliefs on vaccine hesitancy
Huiqiao Zhang, Liyuan Chen, Zhongxuan Huang, Dongxue Li, ... Fan Zhang
Pages 2120-2126

Research article  Open access
Antigenic diversity of type 1 polioviruses and its implications for the efficacy of polio vaccines
Diana Kouiavskaia, Olga Mirochnitchenko, Stephanie Troy, Konstantin Chumakov
Pages 2147-2154

Research article  Abstract only
Factors associated with yellow fever vaccine failure: A systematic literature review
Francieli Fontana Sutile Tardetti Fantinato, Virginia Kagure Wachira, Victor Bertollo Gomes Porto, Henry Maia Peixoto, Elisabeth Carmen Duarte
Pages 2155-2169

Research article  Abstract only
The association between maternal influenza vaccination during pregnancy and adverse birth outcomes in the United States: Pregnancy risk Assessment Monitoring System (PRAMS)
Shuai Xie, Karine Monteiro, Annie Gjelsvik
Pages 2300-2306
Implementation and Delivery of Oral Cholera Vaccination Campaigns in Humanitarian Crisis Settings among Rohingya Myanmar nationals in Cox’s Bazar, Bangladesh
by Ashraful Islam Khan, et al.

Abstract
Background: Over 700,000 Myanmar nationals known as the ‘Rohingyas’ fled into Cox’s Bazar, Bangladesh, in late 2017. Due to this huge displacement into unhygienic areas, these people became vulnerable to communicable diseases including cholera. Assessing the risk, the Government of Bangladesh (GoB), with the help of the International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B) and other international partners, decided to take preventive measures, one of which is the execution of oral cholera vaccination (OCV) campaigns. This paper describes the implementation and delivery of OCV campaigns during humanitarian crises in Bangladesh.
Methods: Seven rounds of OCV campaigns were conducted between October 2017 and December 2021. The OCV campaigns were conducted by applying different strategies.
Results: Approximately 900,000 Rohingya Myanmar nationals (RMNs) and the host population (amounting to 528,297) received OCV across seven campaigns. In total, 4,661,187 doses of OCVs were administered, which included 765,499 doses for RMNs, and 895,688 doses for the host community. The vaccine was well accepted, and as a result, a high level of coverage was achieved, ranging from 87% to 108% in different campaigns.
Conclusions: After successful pre-emptive campaigns in Cox’s Bazar humanitarian camps, no cholera outbreaks were detected either in the RMN or host communities.
The impact of surveillance and other factors on detection of emergent and circulating vaccine derived polioviruses [version 3; peer review: 2 approved, 1 approved with reservations]
Megan Auzenbergs, Holly Fountain, Grace Macklin, Hil Lyons, Kathleen M O'Reilly
Peer Reviewers Yvonne Maldonado; Walter A. Orenstein; Svea Closser
Funder
Bill and Melinda Gates Foundation
LATEST VERSION PUBLISHED 11 Apr 2023
Circulating vaccine derived poliovirus (cVDPV) outbreaks remain a threat to polio eradication. To reduce cases of polio from cVDPV of serotype 2, the serotype 2 component of the vaccine has been removed from the global vaccine supply, but outbreaks of cVDPV2 have continued. The objective of this work is to understand the factors associated with later detection in order to improve detection of these unwanted events.

medRxiv
https://www.medrxiv.org/content/about-medrxiv
[Accessed 15 Apr 2023]
[Filter: All articles]
A Randomised Controlled Trial of Nasal Immunisation with Live Virulence Attenuated Streptococcus pneumoniae Strains using Human Infection Challenge

Optimizing rabies vaccination of dogs in India
Kim Cuddington, William H.B. McAuliffe
medRxiv 2023.04.10.23288318; doi: https://doi.org/10.1101/2023.04.10.23288318

Estimating COVID-19 Vaccine Protection Rates via Dynamic Epidemiological Models–A Study of Ten Countries
Yuru Zhu, Jia Gu, Yumou Qiu, Song Xi Chen
medRxiv 2022.08.08.22278571; doi: https://doi.org/10.1101/2022.08.08.22278571 Revision

OSF Pre-prints
https://osf.io/preprints/discover?provider=OSF&subject=bepress%7_CLife%20Sciences
[Accessed 15 Apr 2023]
[Provider Filter: OSF Pre-prints  Subject filters: Arts & Humanities; Education, Life Sciences; Medicine and Health Sciences; Social and Behavioral Sciences]
We observe increasing levels of “posting pollution” by individuals, sometimes posting 10+ items of no value. If this continues, we may decide to no longer monitor this resource.

**Open-endedness in synthetic biology: a route to continual innovation for biological design**
Michiel Stock, Thomas Gorochowski
Last edited: Apr 13, 2023 UTC
*Life Sciences Biotechnology*

**Abstract**
Design in synthetic biology is typically goal-oriented: aiming to repurpose and optimize existing biological functions for new contexts, augmenting biology with new-to-nature capabilities, or creating life-like systems from scratch. While the field has seen many advances over the past two decades, bottlenecks in the complexity of the systems built are emerging and designs that function in the lab often fail when used in real-world contexts. Here, we propose an open-ended approach to biological design that aims to continuously generate innovative solutions capable of overcoming such hurdles. The fundamental principle we put forward is that the novelty of designed biology, be it a protein, genetic construct or organism, is at least as important as how well it fulfils its goal. Designing with novelty in mind, rather than a sole focus on optimization towards a single “best” design, may allow us to move beyond the diminishing returns we see in performance for most engineered biology to date. Research from the artificial life and evolutionary computing communities has demonstrated that embracing novelty can allow for the automatic generation of innovative and surprising solutions to challenging problems that move us beyond local optima. Synthetic biology now offers the ideal playground to test these ideas in living systems and explore more creative approaches to biological design.

OSF Preprints

**Wellcome Open Research**
https://wellcomeopenresearch.org/browse/articles
[Accessed 15 Apr 2023]
*Selected Research*
*Research Article  Open Access*

**REVISED - Effectiveness of seasonal malaria chemoprevention administered in a mass campaign in the Kedougou region of Senegal in 2016: a case-control study** [version 3; peer review: 1 approved, 1 approved with reservations]
Isaac Akhenaton Manga, et al.

**Abstract**
Background: Seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine (SPAQ) is a malaria prevention strategy recommended since 2012 by the World Health Organization (WHO) for children under 5 years. In Senegal, the scaling up of SMC started in 2013 in the south-eastern regions of the country with an extension of the target to 10 years old children. The scaling up of SMC requires regular evaluation of the strategy as recommended by the WHO. This study was conducted to evaluate the effectiveness of SMC.

*  *  *  *  *

**Think Tanks**
Recalibrating assumptions on AI

Many of the assumptions that underpin current AI policies are entrenched despite the fact that they are unproven and face criticism for not representing the interests of all stakeholders.
12 April 2023
Latest Publications [Selected]
No new digest content identified.

Rand [to 15 Apr 2023]
https://www.rand.org/pubs.html
Published Research [Selected]
No new digest content identified.

Urban Institute [to 15 Apr 2023]
https://www.urban.org/publications
New Research Publications - Selected

World Economic Forum [to 15 Apr 2023]
https://agenda.weforum.org/news/
Media
No new digest content identified.

* * * * *
* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

........

Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

........

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable
development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.